Small molecule · Inhibitor of BCR-ABL1 fusion protein (ABL1 kinase) (ABL1) · developed by Novartis
Asciminib is an orally bioavailable, allosteric BCR-ABL1 tyrosine kinase inhibitor that binds the myristoyl pocket of the BCR::ABL1 fusion protein, distinct from the ATP-binding site, and inhibits wild-type and mutant forms including T315I. It is being studied in Philadelphia chromosome-positive leukemias, including chronic myelogenous leukemia and acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07387926 | Phase 1/2 | Acute Lymphoblastic Leukemia | Recruiting | NVS |
| NCT07936266 | Phase 1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositivePhiladelphia Chromosome-Positive
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →